Patents Assigned to Emory University
  • Therapeutic use of CD31 expressing cells
    Patent number: 10787641
    Abstract: The present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: September 29, 2020
    Assignee: Emory University
    Inventors: Young-sup Yoon, Hyun-Jai Cho
  • CAS9 NUCLEIC ACID MOLECULES AND THEIR USE
    Publication number: 20200299722
    Abstract: Described are recombinant nucleic acid molecules for increased expression of Cas9 in human liver. In some embodiments, the recombinant nucleic acid molecules are provided in compositions and methods for gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).
    Type: Application
    Filed: June 8, 2020
    Publication date: September 24, 2020
    Applicant: Emory University
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection
    Patent number: 10765679
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 8, 2020
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Christina Gavegnano
  • Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
    Patent number: 10759803
    Abstract: This disclosure relates to asparagine endopeptidase inhibitors for managing cancer and compositions related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are substituted 3,7-dihydropurine-2,6-dione derivatives useful for treating or preventing metastasis, tumor growth, and/or cancer. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. In certain embodiments, the disclosure relates to methods of treating a cancer comprising administering an effective amount of pharmaceutical composition a asparagine endopeptidase inhibitor disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: September 1, 2020
    Assignee: Emory University
    Inventors: Keqiang Ye, Haian Fu, Yuhong Du
  • Elimination of hepatitis B virus with antiviral agents
    Patent number: 10752584
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: August 25, 2020
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Sebastien Boucle, Franck Amblard, Ozkan Sari, Leda Bassit
  • Polynucleotide based movement, kits and methods related thereto
    Patent number: 10738349
    Abstract: This disclosure relates DNA based movement of objects. In certain embodiments, particles, pairs of particles, or a rods are conjugated with single stranded DNA that hybridizes to a single stranded RNA that is conjugated to a substrate. When the DNA particle, pair of particles, or rod interacts with the surface RNA in the presence of an endonuclease, such as RNase H and the DNA hybridizes to the RNA, then the particle, pair of particle, or rod moves along the surface. The complementarity of the DNA and RNA affect the velocity.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: August 11, 2020
    Assignee: Emory University
    Inventors: Khalid Salaita, Kevin Yehl
  • Compositions and methods for managing respiratory conditions
    Patent number: 10738079
    Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: August 11, 2020
    Assignee: Emory University
    Inventors: Michael Koval, Barbara Schlingmann
  • HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
    Patent number: 10729762
    Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 4, 2020
    Assignee: Emory University
    Inventors: Rama Rao Amara, June Scott, Bernard Quigley, Venkateswarlu Chamcha
  • CAS9 nucleic acid molecules and their use
    Patent number: 10724050
    Abstract: Described are recombinant nucleic acid molecules for increased expression of Cas9 in human liver. In some embodiments, the recombinant nucleic acid molecules are provided in compositions and methods for gene editing, specifically using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR).
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: July 28, 2020
    Assignee: Emory University
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Steroid analogues for neuroprotection
    Patent number: 10716795
    Abstract: Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid analogues and methods using the novel steroid analogues for the treatment and prevention of neurodegeneration in a patient following injury to the central nervous system.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: July 21, 2020
    Assignee: Emory University
    Inventors: Christopher MacNevin, Donald G. Stein, Dennis C. Liotta, Iqbal Sayeed, David B. Guthrie, Mark A. Lockwood, Michael G. Natchus
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS
    Publication number: 20200223926
    Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD-1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.
    Type: Application
    Filed: August 23, 2019
    Publication date: July 16, 2020
    Applicants: Emory University, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Rafi Ahmed, Rama Amara, Gordon Freeman, Arlene Sharpe, Daniel Barber, E. John Wherry, Sang-Jun Ha
  • Bis-amines, compositions, and uses related to CXCR4 inhibition
    Patent number: 10709697
    Abstract: This disclosure relates bis-amine compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula (I), salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: July 14, 2020
    Assignees: Emory University, Georgia State University Research Foundation, Inc.
    Inventors: Hyunsuk Shim, Suazette Reid Mooring, Renren Bai
  • Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
    Patent number: 10709708
    Abstract: The invention provides combinations comprising a MERTK inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor and methods of use thereof, including methods of treating disorders such as cancer.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 14, 2020
    Assignees: The University of North Carolina at Chapel Hill, Emory University
    Inventors: Dan Yan, H. Shelton Earp, III, Deborah Ann DeRyckere, Douglas Kim Graham, Jing Wan
  • Lipid disulfide prodrugs and uses related thereto
    Patent number: 10688112
    Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substitutents are disclosed herein.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: June 23, 2020
    Assignee: Emory University
    Inventors: Dennis Liotta, Kyle Giesler
  • Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
    Patent number: 10682393
    Abstract: The disclosure relates to therapeutic methods for regulating weight gain, metabolic syndrome, and insulin resistance. In certain embodiments, the disclosure relates to methods of treating or preventing obesity, metabolic syndrome, or insulin resistance by administering an effective amount of a pharmaceutical composition comprising one or more GDNF receptor agonists to a subject in need thereof.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: June 16, 2020
    Assignees: Emory University, The United States Department of Veterans Affairs
    Inventor: Shanthi Srinivasan
  • Phosphoramidates for the treatment of hepatitis B virus
    Patent number: 10683319
    Abstract: Disclosed are compounds to the treatment of infectious diseases and methods of treating such diseases. The compounds are derivatives of clevudine.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 16, 2020
    Assignee: Emory University
    Inventors: Abel de la Rosa, Gregory R. Bluemling
  • Botanical extracts and compounds from Castanea plants and methods of use
    Patent number: 10675321
    Abstract: This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 9, 2020
    Assignees: Emory University, University of Iowa Research Foundation
    Inventors: Cassandra L. Quave, James Lyles, Alexander R. Horswill
  • Botanical extracts and compounds from schinus plants and methods of use
    Patent number: 10675315
    Abstract: This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 9, 2020
    Assignee: Emory University
    Inventors: Cassandra L. Quave, James Lyles
  • Devices and methods related to airway inflammation
    Patent number: 10670594
    Abstract: This disclosure relates to devices, assays, and methods related to airway inflammation caused by polymorphonuclear neutrophils (PMNs). In certain embodiments, the disclosure relates to a model device that emulates the changes in airway cell physiology due to transmigration of PMNs from blood to the cells at the air-liquid interface. In certain embodiments, the airway cells are supported on a collagen layer wherein the collagen layer is further supported by a porous polymer from which PMNs can migrate. In certain embodiments, the disclosure contemplates adding bacteria, fungi and/or viruses to the device to emulate disease states. In certain embodiments, the disclosure relates to the use of the model system to test compounds to identify drug candidates and diagnose subjects with airway-related diseases and conditions.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: June 2, 2020
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventor: Rabindra M. Tirouvanziam
  • Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition
    Patent number: 10669270
    Abstract: This disclosure relates amide-sulfamide compounds disclosed herein and uses related to CXCR4 inhibition. In certain embodiments, the compounds have formula I, salts, derivatives, and prodrugs thereof wherein, A is a bridging aryl or heterocyclyl and R1 and R2 are further disclosed herein. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising compounds disclosed herein. In certain embodiments, the disclosure relates to methods of treating or preventing CXCR4 related diseases or conditions by administering an effective amount of a compound disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: June 2, 2020
    Assignee: Emory University
    Inventors: Hyunsuk Shim, Qi Shi, Renren Bai